TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TEVA - US8816242098 - ADR
31.89 USD
+0.15 (+0.47%)
32.0337 USD
+0.14 (+0.45%)
Taking everything into account, TEVA scores 4 out of 10 in our fundamental rating. TEVA was compared to 192 industry peers in the Pharmaceuticals industry. While TEVA has a great profitability rating, there are quite some concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TEVA had positive earnings in the past year.
TEVA had a positive operating cash flow in the past year.
TEVA had negative earnings in 4 of the past 5 years.
In the past 5 years TEVA always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of TEVA (1.79%) is better than 81.77% of its industry peers.
Looking at the Return On Equity, with a value of 9.82%, TEVA belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 10.63%, TEVA belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
TEVA had an Average Return On Invested Capital over the past 3 years of 9.12%. This is below the industry average of 12.85%.
The last Return On Invested Capital (10.63%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 9.82% | ||
| ROIC | 10.63% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
Looking at the Profit Margin, with a value of 4.24%, TEVA belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
The Operating Margin of TEVA (22.76%) is better than 90.10% of its industry peers.
TEVA's Operating Margin has improved in the last couple of years.
TEVA's Gross Margin of 51.33% is fine compared to the rest of the industry. TEVA outperforms 64.06% of its industry peers.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.76% | ||
| PM (TTM) | 4.24% | ||
| GM | 51.33% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TEVA has more shares outstanding
Compared to 5 years ago, TEVA has more shares outstanding
TEVA has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.94, we must say that TEVA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TEVA (0.94) is comparable to the rest of the industry.
The Debt to FCF ratio of TEVA is 29.05, which is on the high side as it means it would take TEVA, 29.05 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of TEVA (29.05) is better than 74.48% of its industry peers.
TEVA has a Debt/Equity ratio of 2.32. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.32, TEVA is doing worse than 78.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 29.05 | ||
| Altman-Z | 0.94 |
ROIC/WACC1.29
WACC8.25%
2.3 Liquidity
TEVA has a Current Ratio of 1.11. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.11, TEVA is doing worse than 82.29% of the companies in the same industry.
A Quick Ratio of 0.82 indicates that TEVA may have some problems paying its short term obligations.
With a Quick ratio value of 0.82, TEVA is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The earnings per share for TEVA have decreased by -3.96% in the last year.
TEVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.18% yearly.
The Revenue has been growing slightly by 0.02% in the past year.
TEVA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.41% yearly.
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)0.02%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
3.2 Future
TEVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.13% yearly.
Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 1.76% on average per year.
EPS Next Y8.54%
EPS Next 2Y5.56%
EPS Next 3Y8.13%
EPS Next 5YN/A
Revenue Next Year3.29%
Revenue Next 2Y1.8%
Revenue Next 3Y1.76%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.77 indicates a reasonable valuation of TEVA.
TEVA's Price/Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 89.58% of the companies in the same industry.
When comparing the Price/Earnings ratio of TEVA to the average of the S&P500 Index (26.57), we can say TEVA is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 11.33, the valuation of TEVA can be described as reasonable.
85.94% of the companies in the same industry are more expensive than TEVA, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 24.04. TEVA is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.77 | ||
| Fwd PE | 11.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 86.46% of the companies listed in the same industry.
TEVA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TEVA is cheaper than 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 63.29 | ||
| EV/EBITDA | 10.56 |
4.3 Compensation for Growth
TEVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)1.38
PEG (5Y)N/A
EPS Next 2Y5.56%
EPS Next 3Y8.13%
5. Dividend
5.1 Amount
TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
31.89
+0.15 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.54%
Inst Owner Change-9.16%
Ins Owners0.43%
Ins Owner Change-1.57%
Market Cap36.58B
Revenue(TTM)16.78B
Net Income(TTM)712.00M
Analysts82.86
Price Target0.11 (-99.66%)
Short Float %4.06%
Short Ratio3.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.58%
Min EPS beat(2)4.65%
Max EPS beat(2)16.51%
EPS beat(4)4
Avg EPS beat(4)7.25%
Min EPS beat(4)2.01%
Max EPS beat(4)16.51%
EPS beat(8)7
Avg EPS beat(8)7.06%
EPS beat(12)8
Avg EPS beat(12)1.63%
EPS beat(16)10
Avg EPS beat(16)1.03%
Revenue beat(2)1
Avg Revenue beat(2)-1.93%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-1.98%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)0.9%
Revenue beat(8)5
Avg Revenue beat(8)0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.43%
Revenue beat(16)7
Avg Revenue beat(16)-1.36%
PT rev (1m)93.03%
PT rev (3m)93.38%
EPS NQ rev (1m)-1.18%
EPS NQ rev (3m)-3.48%
EPS NY rev (1m)3.17%
EPS NY rev (3m)3.17%
Revenue NQ rev (1m)-0.6%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0.49%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.77 | ||
| Fwd PE | 11.33 | ||
| P/S | 2.18 | ||
| P/FCF | 63.29 | ||
| P/OCF | 34.32 | ||
| P/B | 5.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.56 |
EPS(TTM)2.71
EY8.5%
EPS(NY)2.82
Fwd EY8.83%
FCF(TTM)0.5
FCFY1.58%
OCF(TTM)0.93
OCFY2.91%
SpS14.62
BVpS6.32
TBVpS-11.01
PEG (NY)1.38
PEG (5Y)N/A
Graham Number19.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 9.82% | ||
| ROCE | 13.46% | ||
| ROIC | 10.63% | ||
| ROICexc | 11.52% | ||
| ROICexgc | 47.85% | ||
| OM | 22.76% | ||
| PM (TTM) | 4.24% | ||
| GM | 51.33% | ||
| FCFM | 3.45% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score7
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 29.05 | ||
| Debt/EBITDA | 3.48 | ||
| Cap/Depr | 48.27% | ||
| Cap/Sales | 2.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 22.08% | ||
| Profit Quality | 81.18% | ||
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 0.94 |
F-Score7
WACC8.25%
ROIC/WACC1.29
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y8.54%
EPS Next 2Y5.56%
EPS Next 3Y8.13%
EPS Next 5YN/A
Revenue 1Y (TTM)0.02%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
Revenue Next Year3.29%
Revenue Next 2Y1.8%
Revenue Next 3Y1.76%
Revenue Next 5YN/A
EBIT growth 1Y-3.39%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.41%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-4.93%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-7.87%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 7 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 11.77 and the Price/Book (PB) ratio is 5.05.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.